LONDON – The U.K. Medicines and Healthcare products Agency (MHRA) has followed the U.S. FDA's lead and ordered an investigation into the safety of paclitaxel eluting balloons and stents in the treatment of peripheral arterial disease.

Cambridge, Mass.-based startup Trinetx Inc. has raised a $40 million series D to better match patients with clinical trials and real-world evidence efforts. Merck Global Health Innovation Fund, the $500 million digital-health focused strategic fund of Merck & Co. Inc., led the financing. It boosted the total raised by the company to more than $102 million. New investors Mitsui & Co., Itochu Technology Ventures, Itochu Corp. and existing investors MPM Capital, F2 Ventures and Deerfield Management also participated in the latest round.